What's new on the antimicrobial horizon?

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 4, 2008, Pages

  Song, Jae Hoon ^a  

^a Samsung Medical Center   (South Korea)

Author keywords

Cephalosporin; Diaminopyrimidine; Doripenem; Glycopeptide; Glycylcycline; Lipopeptide

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; DW 286A; ERYTHROMYCIN; GENTAMICIN; ICLAPRIM; IMIPENEM; LINEZOLID; MEROPENEM; NAFCILLIN; ORITAVANCIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TELAVANCIN; TIGECYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; GASTROINTESTINAL SYMPTOM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; RED MAN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 58149143261     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70004-4     Document Type: Article

References (38)

1. Wenzel R.P. The antibiotic pipeline - challenges, costs, and values. N Engl J Med 351 (2004) 523-526
2. Rice L.B. Do we really need new anti-infective drugs?. Curr Opin Pharmacol 3 (2003) 459-463
3. Esposito A.L., and Gleckman R.A. Vancomycin: a second look. J Am Med Assoc 238 (1977) 1756-1757
4. Geraci J.E., and Wilson W.R. Vancomycin therapy for infective endocarditis. Rev Infect Dis 3 Suppl (1981) S250-S258
5. Small P.M., and Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34 (1990) 1227-1231
6. Chang F.Y., Peacock Jr. J.E., Musher D.M., Triplett P., MacDonald B.B., Mylotte J.M., et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82 (2003) 333-339
7. Infectious Diseases Society of America. FDA lowers vancomycin breakpoints for staph infections (2007), Infectious Diseases Society of America, Arlington, VA. http://idsociety.org/newsArticle.aspx?id=11388 [accessed 28 June 2008].
8. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30 (2004) 388-394
9. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin Infect Dis 42 Suppl 1 (2006) S51-S57
10. Kollef M.H. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 45 Suppl 3 (2007) S191-S195
11. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 Suppl 1 (2006) S35-S39
12. Cruciani M., Gatti G., Lazzarini L., Furlan G., Broccali G., Malena M., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38 (1996) 865-869
13. Lamer C., de Beco V., Soler P., Calvat S., Fagon J.Y., Dombret M.C., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37 (1993) 281-286
14. LaPlate K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48 (2004) 4665-4675
15. Sakoulas G., Moise-Bender P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of meticillin-resistant Staphyloccous aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
16. Hidayat L.K., Lau D., Quist R., Shriner K.A., and Wong-Beringer A. High-dose vancomycin therapy for meticillin-resistant Staphylococcus infections: efficacy and toxicity. Arch Intern Med 166 (2006) 2138-2144
17. Jeffres M.N., Isakow W., Doherty J.A., Micek S.T., and Kollef M.H. A retrospective study of possible renal toxicity in patients with healthcare-associated meticillin-resistant Staphylococcus aureus pneumonia treated with vancomycin. Clin Ther 29 (2007) 1107-1115
18. Micek S.T. Alternatives to vancomycin for the treatment of meticillin-resistant Staphylococcus aureus infections. Clin Infect Dis 45 Suppl 3 (2007) S184-S190
19. Billeter M., Zervos M.J., Chen A.Y., Dalovisio J.R., and Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 46 (2008) 577-583
20. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 (2005) 1407-1415
21. Attwood R.J., and LaPlante K.L. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64 (2007) 2335-2348
22. Stryjewski M.E., O'Riordan W.D., Lau W.K., Pien F.D., Dunbar L.M., Vallee M., et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 40 (2005) 1601-1607
23. Stryjewski M.E., Chu V.H., O'Riordan W.D., Warren B.L., Dunbar L.M., Young D.M., et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50 (2006) 862-867
24. Enoch D.A., Bygott J.M., Daly M.-L., and Karas J.A. Daptomycin. J Infect 55 (2007) 205-213
25. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I., and Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
26. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., and Rupp M.E. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
27. Silverman J.A., Mortin L.I., VanPraagh A., Li T., and Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
28. Noel G.J. Clinical profile of ceftobiprole, a novel β-lactam antibiotic. Clin Microbiol Infect 13 Suppl 2 (2007) 25-29
29. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 4210-4219
30. Jones R.N., Deshpande L.M., Mutnick A.H., and Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 50 (2002) 915-932
31. Zbinden R., Pünter V., and von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against Gram-negative nonfermenters. Antimicrob Agents Chemother 46 (2002) 871-874
32. Schneider P., Hawser S., and Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13 (2003) 4217-4221
33. Stevens DL, Leighton A, Danker W, Hadváry P. Efficacy of iclaprim in complicated skin and skin structure infections: preliminary results of ASSIST-1. Presented at 45th IDSA, 4-7 October 2007, San Diego, USA. Abstract 1104.
34. Shah P.M. The need for new therapeutic agents: what is in the pipeline?. Clin Microbiol Infect 11 Suppl 3 (2005) 36-42
35. Greer N.D. Doripenem (Doribax): the newest addition to the carbapenems. Proc Baylor Univ Med Cent 21 (2008) 337-341
36. Jones R.N., Huynh H.K., and Biedenbach D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 48 (2004) 3136-3140
37. Fritsche T.R., Stilwell M.G., and Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 11 (2005) 974-984
38. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., and Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36 (2008) 1089-1096